代谢组学视角下的轻度认知障碍生物标志物研究进展
Progress on biomarkers of mild cognitive impairment from the perspective of metabolomics
代丛姗 1种玉飞 2夏文广 2刘万红3
作者信息
- 1. 湖北省直属机关医院(湖北省康复医院),湖北武汉 430071;武汉大学泰康医学院(基础医学院)过敏及免疫湖北省重点实验室,湖北武汉 430071
- 2. 湖北省直属机关医院(湖北省康复医院),湖北武汉 430071
- 3. 武汉大学泰康医学院(基础医学院)过敏及免疫湖北省重点实验室,湖北武汉 430071
- 折叠
摘要
轻度认知障碍的实际发病率较高,对人们的日常生活影响较大,但是其发现较为困难,这对该疾病的早期诊断与治疗以及病程监测等方面提出了全新的挑战.轻度认知障碍生物标志物的发现将为该疾病的诊疗提供适时的帮助,最近,代谢组学技术在轻度认知障碍的生物标志物发现方面展示了许多新的研究结果.综述了近期代谢组学技术在轻度认知障碍研究中的重要发现,包括关键代谢物的鉴定、代谢途径的异常及其与轻度认知障碍病理生理过程的联系等.代谢组学技术的应用将为轻度认知障碍的早期诊断及个性化治疗等领域的发展提供新的思路和重要理论基础.
Abstract
The actual incidence rate of mild cognitive impairment(MCI)is relatively high,and it has a significant impact on people's well-being,but its discovery is relatively difficult,which poses a new challenge for early diagnosis treatment and the monitoring of the course of the disease.Biomarkers for MCI could provide timely assistance in its diag-nosis and treatment.Recently,metabolomics technology has demonstrated promising results in identifying biomarkers for MCI.Therefore we review the key findings of metabolomics in MCI research,including the identification of crucial me-tabolites,abnormalities in metabolic pathways and their association with the pathophysiological processes of MCI.The application of metabolomics technology could provide new insights and important theoretical foundations for the develop-ment of the early diagnosis,precision medicine,and personalized treatment strategies of MCI.
关键词
轻度认知障碍/代谢组学/代谢物/生物标志物Key words
mild cognitive impairment(MCI)/metabolomics/metabolite/biomarker引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据